Post-irradiation intratumoral heterogeneity modulates response to immune checkpoint inhibition therapy in a murine melanoma model.

"Declaration of Competing Interest The authors declare no relevant conflict of interest. Full disclosures are provided. TZ has received research funding to institution from Acerta Pharma, Astellas Pharma, Janssen, Merrimack, Merck, Mirati Therapeutics, Novartis, OmniSeq, Personal Genome Diagnostics, Pfizer, Regeneron, StemCentRx; consulting or advisory roles at Amgen, AstraZeneca, Bristol-Myers Squibb, Calithera Biosciences, Dendreon, Exelixis, Foundation Medicine, Genentech/Roche, Janssen, Pharmacyclics, Pfizer, Sanofi, SeaGen, and QED Therapeutics; Honoraria from Exelixis, Genentech/Roche, MJH Life Science, Pacific Genuity; speaker's bureau at Genomic Health and Sanofi/Aventis; stock and other ownership interests at Archimmune Therapeutics (immediate family member), Capio Biosciences (immediate family member), and Nanorobotics (immediate family member). AZW has received research funding from Varian and is a cofounder of Archimmune Therapeutics and Capio Sciences. He also serves on the scientific board of Nanorobotics."

"Funding This work as supported by the University Cancer Research Fund from the University of North Carolina. A.Z.W. was also supported by the National Institutes of Health Center for Nanotechnology Excellence Grant U54-CA151652 and R01CA178748."